A resolution designating July 15, 2026, as "Glioblastoma Awareness Day".
- Bill Number
- S.Res. 786
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Passed Senate
- Latest Action
- 2026-06-23: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S3052; text: CR S3061-3062)
- Last Updated
- 2026-07-08T21:31:33Z
AI-Generated Summary
Purpose
The legislation designates July 15, 2026, as "Glioblastoma Awareness Day" to highlight the challenges of this brain cancer, promote public understanding of its unmet medical needs, and encourage research and treatment advancements.
Key Provisions
- Background facts on glioblastoma: Notes that over 13,000 people in the United States are expected to be diagnosed in 2026, with more than 10,000 deaths annually. It describes the disease as the most common and aggressive malignant brain tumor, with a 5-year survival rate of only 7 percent and a median survival of 8 months.
- Challenges highlighted: Emphasizes difficulties in treatment due to the brain's complexity, high out-of-pocket costs for patients, lack of screening methods, and limited approved treatments (only 5 drugs and 1 device since the 1920s).
- Recent developments: References 2021 updates to molecular diagnosis requiring biomarker testing, and the 2020 establishment of the Glioblastoma Therapeutics Network by the National Cancer Institute.
- Resolved actions:
- Officially designates the awareness day.
- Encourages greater public awareness.
- Honors those affected by the disease.
- Supports better treatments to improve prognosis and quality of life.
- Recognizes the role of molecular biomarker testing.
- Expresses support for patients, families, and caregivers.
- Urges collaboration among government, private, and nonprofit groups.
- Encourages continued investments in research, including through the Glioblastoma Therapeutics Network.
Significant Changes to Existing Law
This resolution introduces no amendments or alterations to existing statutes. It serves as a non-binding Senate declaration focused on awareness and support rather than creating new legal requirements.
Potential Impacts
- On government agencies: Promotes ongoing federal involvement in research through entities like the National Cancer Institute and encourages investments in brain tumor studies.
- On citizens: Aims to increase understanding of glioblastoma among the public, potentially leading to more support for affected individuals and advocacy for research.
- On international relations: No direct effects outlined in the document.
Main Stakeholders Affected
- Individuals diagnosed with glioblastoma and their families.
- Caregivers and survivors.
- Medical researchers and organizations involved in brain tumor studies.
- Government bodies such as the National Cancer Institute and Food and Drug Administration.
- Nonprofit groups focused on cancer research.
Notable Legal, Constitutional, or Political Implications
The resolution has no binding legal force and raises no constitutional concerns, as it is a symbolic designation without regulatory changes. It politically emphasizes the need for collaborative research efforts and recognizes biomarker testing as important for diagnosis, while highlighting persistent gaps in treatment options over decades.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (9)
Sen. Kelly, Mark [D-AZ], Sen. Barrasso, John [R-WY], Sen. Scott, Tim [R-SC], Sen. Van Hollen, Chris [D-MD], Sen. Markey, Edward J. [D-MA], Sen. Warren, Elizabeth [D-MA], Sen. Coons, Christopher A. [D-DE], Sen. Gallego, Ruben [D-AZ], Sen. Shaheen, Jeanne [D-NH]
Recent Actions
- 2026-06-23: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S3052; text: CR S3061-3062)
- 2026-06-23: Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent.
Bill Versions
- Designating July 15, 2026, as "Glioblastoma Awareness Day". — issued 2026-06-23 — PDF (4 pages)